Vimta Labs Ltd
Vimta Labs Limited is testing food and drugs. It also does contract research for clinical research and pre-clinical studies provider in India. It provides analytical, clinical and preclinical services to life sciences industries; quality and safety testing for food and beverage industries; and environment services to a wide spectrum of industries. [1][2]
- Market Cap ₹ 1,242 Cr.
- Current Price ₹ 560
- High / Low ₹ 623 / 365
- Stock P/E 31.6
- Book Value ₹ 133
- Dividend Yield 0.36 %
- ROCE 24.3 %
- ROE 18.4 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 23.6% CAGR over last 5 years
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
87 | 109 | 127 | 116 | 138 | 154 | 183 | 213 | 181 | 209 | 276 | 315 | 315 | |
86 | 88 | 101 | 99 | 119 | 127 | 138 | 155 | 151 | 156 | 196 | 221 | 232 | |
Operating Profit | 1 | 21 | 26 | 17 | 19 | 27 | 45 | 58 | 30 | 53 | 80 | 94 | 84 |
OPM % | 1% | 19% | 20% | 15% | 14% | 18% | 25% | 27% | 17% | 25% | 29% | 30% | 26% |
3 | 1 | 3 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 0 | 3 | 4 | |
Interest | 4 | 3 | 2 | 1 | 1 | 2 | 5 | 5 | 4 | 2 | 2 | 3 | 2 |
Depreciation | 16 | 15 | 9 | 11 | 10 | 10 | 16 | 20 | 21 | 23 | 23 | 31 | 34 |
Profit before tax | -16 | 4 | 18 | 7 | 8 | 17 | 26 | 35 | 8 | 28 | 55 | 64 | 52 |
Tax % | 4% | 4% | 25% | 24% | 23% | 36% | 36% | 28% | 17% | 25% | 26% | 26% | |
-15 | 4 | 13 | 5 | 6 | 11 | 16 | 25 | 7 | 21 | 41 | 47 | 39 | |
EPS in Rs | -6.96 | 1.90 | 5.99 | 2.29 | 2.91 | 4.79 | 7.43 | 11.45 | 3.13 | 9.62 | 18.57 | 21.37 | 17.73 |
Dividend Payout % | 0% | 32% | 33% | 44% | 34% | 0% | 27% | 17% | 0% | 21% | 11% | 9% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | 11% |
3 Years: | 20% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 27% |
5 Years: | 24% |
3 Years: | 91% |
TTM: | -16% |
Stock Price CAGR | |
---|---|
10 Years: | 18% |
5 Years: | 24% |
3 Years: | 24% |
1 Year: | 45% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 14% |
3 Years: | 17% |
Last Year: | 18% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Reserves | 105 | 108 | 116 | 118 | 122 | 132 | 148 | 167 | 169 | 190 | 229 | 276 | 290 |
21 | 12 | 7 | 4 | 26 | 44 | 40 | 26 | 32 | 30 | 19 | 15 | 19 | |
26 | 21 | 22 | 21 | 23 | 42 | 40 | 40 | 39 | 49 | 54 | 65 | 60 | |
Total Liabilities | 156 | 145 | 149 | 146 | 176 | 222 | 232 | 237 | 245 | 273 | 306 | 360 | 374 |
105 | 93 | 90 | 88 | 88 | 88 | 140 | 135 | 131 | 128 | 162 | 168 | 174 | |
CWIP | 0 | 0 | 2 | 0 | 6 | 53 | 0 | 4 | 2 | 17 | 0 | 12 | 26 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 6 | 6 | 6 |
51 | 51 | 57 | 58 | 82 | 80 | 92 | 99 | 105 | 122 | 138 | 174 | 168 | |
Total Assets | 156 | 145 | 149 | 146 | 176 | 222 | 232 | 237 | 245 | 273 | 306 | 360 | 374 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
13 | 16 | 17 | 15 | -1 | 24 | 33 | 39 | 24 | 37 | 59 | 87 | |
-4 | -4 | -8 | -8 | -16 | -39 | -24 | -16 | -20 | -32 | -38 | -57 | |
-9 | -11 | -8 | -9 | 19 | 13 | -8 | -23 | -1 | -5 | -16 | -11 | |
Net Cash Flow | -0 | 1 | 0 | -1 | 2 | -2 | 1 | 1 | 3 | 1 | 5 | 19 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 107 | 87 | 81 | 82 | 100 | 101 | 111 | 100 | 117 | 128 | 102 | 93 |
Inventory Days | 184 | 165 | 175 | 158 | 213 | 183 | 209 | 199 | 191 | 140 | 115 | 187 |
Days Payable | 193 | 147 | 87 | 66 | 77 | 184 | 148 | 115 | 114 | 139 | 81 | 119 |
Cash Conversion Cycle | 98 | 105 | 169 | 174 | 236 | 100 | 172 | 184 | 194 | 128 | 136 | 160 |
Working Capital Days | 59 | 88 | 84 | 120 | 126 | 68 | 88 | 87 | 100 | 116 | 96 | 84 |
ROCE % | -8% | 6% | 16% | 6% | 7% | 11% | 17% | 21% | 6% | 14% | 24% | 24% |
Documents
Announcements
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 16 Apr
-
Compliance Certificate Under Regulation 7(3) For The Year Ended 31.03.2024.
15 Apr - Compliance Certificate under Regulation 7(3) issued by Share Transfer Agent CIL Securities Limited for the year ended 31.03.2024.
-
Compliance Certificate Under Regulation 40(9)
13 Apr - Compliance Certificate issued by Practicing Company Secretary for the year ended 31st March 2024
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Apr - Confirmation Certificate provided by the share transfer agent M/s CIL SECURITIES LTD, for the quarter ended 31st March 2024.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 5 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Oct 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Jun 2020TranscriptPPT
-
Feb 2020TranscriptPPT
-
Nov 2019TranscriptPPT
Services
The company deals in drug life cycle management, development and discovery support services, clinical research, central lab, and cGMP analytical services for pharmaceutical and biopharmaceutical companies.
It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters & regulators, and EMI/EMC testing for electronic and electrical products. [1]